Discovery of novel BTK inhibitors with carboxylic acids
Authors:
- 25 November 2016
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (6) , 1471-1477
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritisDrug Discovery Today, 2014
- Targeting Bruton's tyrosine kinase in B cell malignanciesNature Reviews Cancer, 2014
- Ibrutinib: First Global ApprovalDrugs, 2014
- Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell MalignanciesJournal of Medicinal Chemistry, 2012
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritisNature Chemical Biology, 2010
- B-cell targeting in rheumatoid arthritis and other autoimmune diseasesNature Reviews Immunology, 2006
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemiaCell, 1993
- The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinasesNature, 1993